| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.068 | 0.05 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | -0.28 | 0.05 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.05 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.06 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.06 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | -0.34 | 0.06 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.061 | 0.06 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.056 | 0.06 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.098 | 0.06 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.062 | 0.07 |